Ofatumumab: a novel monoclonal anti-CD20 antibody
Thomas S LinGlaxoSmithKline Oncology R&D, Collegeville, PA, USAAbstract: Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively in...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Online Access: | http://www.dovepress.com/ofatumumab-a-novel-monoclonal-anti-cd20-antibody-a4409 |